Gastroscholar

Intestinal ultrasound is point-of-care transmural imaging. ECCO-ESGAR 2019 (Maaser, PMID 30137275) and the 2025 ECCO-ESGAR-ESP-IBUS update (Kucharzik, PMID 40741688) put IUS next to MRE for Crohn's small-bowel assessment. Ilvemark 2022 (PMID 34614172): remission is bowel wall thickness 3.0 mm or less with no color Doppler. A thick, hyperemic ileum is not a license to skip the colonoscopy you need for dysplasia, histology, or a stricture you cannot see.

Original GastroScholar summary card for intestinal ultrasound in IBD. Not a clinical ultrasound still.
Original GastroScholar summary card. Not a clinical ultrasound still. This page does not invent bowel-wall images.

Experienced teaching points

Clinical Pearls

  1. IUS is activity and complications, not a Sydney or SCENIC dysplasia exam. Keep the surveillance colonoscopy.
  2. Remission on expert consensus: wall 3.0 mm or less and no color Doppler (Ilvemark, PMID 34614172). Response is a 25% or 2 mm drop, or Doppler down one point plus at least 1 mm.
  3. A 7 mm hyperemic ileum means activity is likely. It does not 'definitively' prove a biologic has failed. Pair it with symptoms, calprotectin, and the question you actually need answered.
  4. Rectum is the usual miss. Obesity, gas, and deep pelvis limit you. Say so in the report instead of calling a normal sigmoid a whole-colon remission.
  5. Dysplasia technique: IBD surveillance. Postoperative Crohn's: Rutgeerts. UC drugs: treat-to-target. Pouch: pouchitis.

GI Endoscopy · 7 min read

IUS in IBD: Transmural Activity at the Bedside, Not a Dysplasia Colonoscopy

Bowel wall thickness plus color Doppler. Response is a drop in thickness. The rectum is a blind spot. Histology still needs a scope.

Clinical Bottom Line

Question Practical IUS answer
What it is for Known IBD activity, response, and complications (abscess, fistula, stricture) without prep or radiation. ECCO-ESGAR 2019 (PMID 30137275). 2025 update keeps IUS or MRE for Crohn's small bowel (PMID 40741688).
Remission Bowel wall thickness 3.0 mm or less and no abnormal color Doppler (Ilvemark expert consensus, PMID 34614172).
Response Thickness down more than 25% or at least 2.0 mm, or Doppler down one point plus thickness down at least 1.0 mm.
STRIDE-II Mucosal healing remains the long-term target. Transmural healing is an adjunct in Crohn's, not a replacement for endoscopy when you need mucosa or histology (Turner, PMID 33359090).
What it is not Not a dysplasia survey. Not a substitute for ileocolonoscopy at diagnosis. Poor for rectum. Operator-dependent.

Can IUS replace the scope?

No, and that is the honest answer to the leftover copy on this URL. The prior stub treated a 7 mm hyperemic ileum as proof a biologic had failed and called colonoscopy prep "brutal." Thickness plus Doppler is a transmural biomarker. It is not histology, it is not chromoendoscopy, and it does not see the rectum well. Use it to decide whether activity is still there on a Tuesday afternoon. Book the scope when you need tissue, dysplasia, or a map the probe cannot reach.

Diagnosis of new IBD still wants ileocolonoscopy with biopsies. IUS or MRE then stages small-bowel Crohn's. Monitoring is where IUS earns its keep: treat-to-target visits, pregnancy, kids, and anyone who will not do another prep for a yes/no activity question. Say when the study is limited (gas, body habitus, surgical anatomy).

How do you call response?

Ilvemark 2022 (PMID 34614172) is the language to quote. Remission: wall 3.0 mm or less, no color Doppler. Response: a clear drop in thickness, with or without a Doppler improvement. Do not invent a center-specific cutoff and call it "the IBUS score" unless you are actually using a named, published score your group trained on. STRIDE-II (PMID 33359090) still wants endoscopic mucosal healing as the long-term Crohn's target. Transmural healing on IUS or MRE is useful extra information, not a reason to skip surveillance.

Complications: IUS finds many abscesses and fistulas at the bedside. Cross-section still wins for deep pelvis and preoperative anatomy. Do not restage SCENIC technique, Rutgeerts scoring, or UC drug choice here.

Selected references

  1. Kucharzik T, et al. ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1. J Crohns Colitis. 2025;19:jjaf106.
  2. Maaser C, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1. J Crohns Colitis. 2019;13:144-164.
  3. Ilvemark JFKF, et al. Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease. J Crohns Colitis. 2022;16:554-580.
  4. Turner D, et al. STRIDE-II: An Update on Selecting Therapeutic Targets in Inflammatory Bowel Disease. Gastroenterology. 2021;160:1570-1583.

Last reviewed September 20, 2026. Written for clinicians who want a same-visit transmural read on Crohn's or UC activity without booking another colonoscopy for every flare question.

For your teaching file

Save this article as a PDF

Drop your email and we'll open a print-ready version you can save as a PDF — and you'll start getting our weekly GI endoscopy newsletter.

Save as PDF

Transabdominal Intestinal Ultrasound (IUS) in Crohn’s Disease

Enter your email — we'll open a clean print-ready version of this article. Choose Save as PDF in the print dialog to download.

Free, no spam. Gastroscholar newsletter. Unsubscribe anytime.

← All articles